Introduction
Tuberculosis (TB) remains numerically the most significant single infectious cause of morbidity and mortality, infecting 8 million and killing 3 million people annually,'> and causing approximately onequarter of all avoidable adult deaths from infe~tion.~ The steady decline in cases of clinical TB seen in the developed, and parts of the developing world, ceased ' or reversed in the mid-1980s. In the USA, there was an increase of 18.4 % in reported cases of TB between 1985 and 1991,4 corresponding to an excess of 28000 cases over the number expected between 1985 and 1990 (increasing to over 60000 cases by 1993) had the decline ~ontinued.~ Untreated, the mortality rate of clinical disease is 40-60 %, 6 a tragedy in view of the proven efficacy of chemotherapeutic regimens.'-* There are several possible explanations, or combinations of explanations, for the increase in cases of active TB worldwide. These vary in importance depending on the particular geographic location, but include: (a) co-infection with the human immunodeficiency virus (HIV), the single most important risk factor for progression from dormancy to clinical Received 27 Jan. 1995; accepted 20 Feb. 1995. disease; (b) failure to give priority to national TB control programmes, or poorly organised programmes with poor case finding, treatment rates and compliance; (c) reduction or withdrawal of donor agency support to international TB control programmes in the developing world; (d) increasing numbers of homeless people sheltering in crowded conditions, as well as overcrowding in institutions such as prisons; (e) intravenous drug abuse; (f) health immunocompromised by extremes of age, alcoholism, diabetes mellitus, renal failure, and infection with other acute immunosuppressive illnesses such as measles and malaria; (g) drug therapy, especially steroids used for the treatment of asthma, rheumatological and connective tissue disorders and transplant rejection ; and (h) increasing immigration. This review considers recent advances in our understanding of clinical, microbiological and epidemiological issues associated with TB in HIV-infected individuals, including diagnosis, treatment and the potential risks of TB in immunosuppressed health care workers (HCWs).
Tuberculosis and HIV co-infection
The Global Programme on AIDS estimated that 16 million adults and 1 million children were infected Co-infection with HIV and TB in children is now a significant health problem. In a recent study in Zambian children, the seroprevalence of HIV-1 in 237 hospitalised children between the ages of 1 month and 14 years with a clinical diagnosis of TB-but not a bacteriologically proven one-was 37 YO compared to 10.7% in a control group of 242 children without TB. 19 Rates of TB among children in the developed world are much lower, except in some urban deprived areas-e.g., the incidence of tuberculosis in New York City rose 300 O/ O between 1987 and 1991, particularly in those aged (3-4 years. Although HIV positivity remains the most important risk factor for clinical TB, a recent study of children in the Bronx, New York, reiterated the role of household overcrowding and poverty in transmission independently of HIV infection.20
There is less overlap between TB and HIV in the developed world at the present time. In the USA, only 
Clinical TB disease in AIDS patients
In general, TB occurs at an early stage in HIV infection when the CD4 lymphocyte count can be in the normal range or only slightly below it, in contrast to infection with M . avium-intracellulare which is associated with very low CD4 counts, typically < 75 mm3. The diagnosis of TB depends on clinical symptoms and signs, tuberculin testing, radiology, and the microscopic examination and culture of sputum, bronchoscopic samples, cerebrospinal fluid, urine or tissue. Sputum-positive pulmonary disease is the most cornmon presentation in HIV-seronegative patients, but in HIV-infected individuals, focal and disseminated extrapulmonary disease is more common. l8 In immunosuppressed patients, clinical disease may present with atypical clinical and radiological features, including fewer lung cavities and a lower probability of sputum positivity. Anergy may negate the. diagnostic value of tuberculin testing. However, MTB is more likely to be isolated from blood cultures, which may aid diagnosis.30
A recent study in Zambia compared the clinical features of 182 dually-infected patients and 67 HIVseronegative patients with TB. Among HIV-negative patients, 72% had pulmonary disease alone, 16% extrapulmonary disease, and 12 YO both, whereas among HIV-positive patients, the equivalent figures were 40 YO, 34 % and 26 % re~pectively.~~ Only 35 % of HIV-positive cases were sputum-positive, compared with 55 % of HIV-seronegative cases. In those patients presenting with pulmonary disease alone, 57 YO of HIV-positive cases were sputum-positive, compared with 76 % of HIV-negative patients. The tuberculin test was positive in only 27% of HIV-positive cases, compared with 55% of HIV-negative cases. Rates of diagnosis from culture were similar.31
Patients infected with both MTB and HIV are more likely to progress rapidly to clinical TB,32 with an annual risk of 8 YO compared to a lifetime risk of 10 YO for HIV-seronegative subjects ;21 this is probably caused by an immunological potentiation of HIV and MTB in co-infection (see below).
Reactivation or re-infection
TB results primarily from reactivation of endogenous infection, usually many years after primary infection. In a study of 520 i.v. drug abusers in New York City, 23 YO of HIV-positive subjects and 20 YO of HIV-negative subjects had an initial positive tuberculin response (PPD + ve), i.e., previous exposure to MTB. The seroconversion rates to tuberculin positivity over the 22-month follow-up period were similar in both sub-groups at 11 % and 13 YO, i.e., the risk of infection with MTB was the same. Clinical tuberculosis developed in eight (4%) of the HIVpositive patients, but in none of the seronegative group; seven of these eight patients were initially PPD + ve, indicating that the risk of developing clinical disease was increased and was a result of reactivation of latent tuberculosis in the HIV-positive group.33 In the developing world, TB precedes HIV infection, and re-infection occurs against a high background of endemic disease. Whether this is caused by reactivation or recent infection is difficult to demonstrate because of the endemic nature of the infection and the prolonged temporal relationship between infection and clinical disease. Application of molecular techniques such as DNA fingerprinting and PCR should aid our understanding of the epidemiology of TB in these In a Hong Kong study, fingerprints of isolates from five (12 56 In spite of effective chemotherapy for TB, the mortality rate of Africans infected with HIV and TB is high, mainly because of the higher incidence of acute non-tuberculous infections such as pneumococcal or salmonella septicaemia seen in HIV-positive patients. 54 With adequate treatment and compliance, the response to treatment of pulmonary TB in HIVpositive and HIV-negative patients is similar, but HIV-positive patients are more likely to become culture-negative in the first month of treatment, mainly because of the lower mean pre-treatment viable counts of MTB in sputum specimens noted in HIV-positive
The rate of recurrence of TB is increased in HIV patients in the developing world where thiacetazonebased regimens are still employed. Thus, for example, in one prospective study in Kenya, the recurrence rate of TB in HIV-infected patients was 34-fold greater than in HIV-negative patients treated with thiacetazone-containing regimens.58 In addition, serious cutaneous hypersensitivity reactions, including Stevens-Johnson syndrome, are particularly common with thiacetazone-based regimens in HIV patients.58
In one recent study in Zambia, 22 (9 YO) of 237 children developed cutaneous hypersensitivity reactions whilst on a regimen that included thiacetazone; 12 of the 22 children who developed Stevens-Johnson syndrome were HIV-positive. 19 Strains of MDR-MTB have emerged in several countries, with an overall mortality rate of 40-60 YO in HIV-seronegative patients which is equivalent to that %) were resistant to one or more first-line anti-TB drugs. Isoniazid resistance was found in 6.1 O/ O of these strains, with isoniazid and rifampicin resistance in 0.6% of isolates. 63 The actual number of MDR-MTB strains referred to the M R U and the RTC at Dulwich Public Health Laboratory, London, over the past decade has remained at about 80-90 per annum, with c. 80% resistant to isoniazid or streptomycin. Most strains were from migrants, principally from the Indian subcontinent.'6 Unlike recent outbreaks in the USA, there was no association with HIV infection, and there have been no outbreaks involving MDR-MTB strains. 64 Secondary resistance associated with poor compliance is more common in the groups that are likely to develop clinical disease. In one study in New York, 64% of patients were homeless, and 89% of these failed to complete therapy or were lost to follow-up, or both. in the following year, 27 ' / o of these patients were re-admitted with clinical tuberculosis. ' infection with MDR-MTB increases morbidity and mortality significantly, especially in HIV-infected patients. Eight outbreaks caused by MDR-MTB were investigated by the CDC between 1990 and 1992, involving over 300 patients of whom 80 YO were HIVpOSitive. 45 67 In most cases the deaths occurred in HIV-positive individuals, raising the issue of safety for HIV-positive HCWs who care for AIDS patients with TB. However, TB in patients infected with HIV-1 is no more infectious than TB in the immunocompetent. 68 In the USA, concern over the risks posed to HCWs by MDR-MTB strains led to the promulgation of sweeping guidelines by the CDC in 1990 and 1993.69*70 The guidelines included simple individual measures, such as patients covering their mouths when coughing, but included more controversially a series of environmental measures, such as negative pressure isolation rooms with six changes of air each hour and ultraviolet germicidal lamps. Many of the guidelines have been criticised on the grounds of cost, negligible contribution to overall safety, or both. Recommendations for the use of high efficiency particulate (HEPA) respirators for personnel attending infectious patients have come under particular criticism as expensive and unproven. For example, one study estimated that the use of these respirators would cost $7 million per case of TB prevented and $100 million per life saved, and a second concluded that it would cost between $1.3 and $18.5 million to prevent one case at the hospital studied. "* ' * Comparable guidelines have been promulgated in the UK, and also by the International Union Against Tuberculosis and Lung Disease and the World Health Organi~ation.~~, 74 In general, these guidelines argue for the sensible application of less draconian infection control measures, including room isolation and adequate ventilation to the outside environment, BCG vaccination, pre-employment screening and vigorous contact tracing.73 Preventative therapy for TB has also been recommended for HIV-positive patients who yield a positive tuberculin test in the absence of active tuberculosis, with a daily isoniazid dose of 5mg/kg, up to a maximum of 300mg, for 6 1 2 month^.'^ Isoniazid may be given twice weekly at a dose of 15 mg/kg, although there are no clinical studies demonstrating the efficacy of intermittent preventative therapy.75 All cases of tuberculosis in HCWs in the USA have been reviewed e~tensively.'~ Significant advances have been made in our understanding of the mechanisms of drug resistance and drug therapy44-i7-84 which, coupled with the development of rapid methods for determining drug resistance, will be of particular benefit to HIV patients infected with MTB.
Immunology of TB and HIV co-infection
The immunology and pathogenesis of TB is under intensive study,82* 85-87 but is outside the scope of this review. However, the rapid progression of TB in HIVpositive patients does provide some insights into the underlying immunological mechanisms influencing the progression of clinical disease, particularly the importance of the reduction in CD4+ T-lymphocyte number and function (which also occurs to a lesser degree in TB without concurrent HIV infection). CD4+ cells have an important role in inducing cytotoxicity, leading to lysis of infected monocytes20' 85-90 and to the panoply of cytokines released, such as TNF-a, IFN-y, IL1, IL6 and ILlO. Two subsets of T-helper CD4+ lymphocytes, TH1 and TH2, co-ordinate the overall response and inhibit the presence of the other subset. TH1 cells secrete y-IFN and other cytokines responsible for macrophage activation in response to mycobacterial antigens, whilst TH2 cells produce IL4, 5 and 10 which stimulate B cells and antibody production. As HIV disease progresses, the number of THl cells declines, correlating with a reduction in macrophage activity against mycobacterial antigens, the loss of Langhans giant cells, epitheliod macrophages and granuloma formation, and a shift from a paucibacillary to a multibacillary [85] [86] [87] [88] [89] [90] [91] [92] Caseating necrosis is replaced by a suppurative and coagulative necrosis.18* 86 Conversely, HIV replication may be enhanced by the multiplication of MTB in monocytes or macrophages through the up-regulation of transcription, or the increased release of TNF-a and p-2 microg l o b~l i n .~~-~~ The levels of HIV-1 p24 antigen in culture supernates of monocytes taken from patients with active pulmonary TB who were infected subsequently with HIV-1 were significantly higher than for culture supernates of monocytes from non-tuberculous individual^.'^ Enhanced susceptibility to HIV infection or reproduction may be a direct result of monocyte activation by exposure to MTB. Interestingly, studies have now demonstrated that isoniazid prophylaxis given to HIV-positive individuals also infected with MTB, but not exhibiting active disease, may delay the progression of HIV 98 Isoniazid prophylaxis given to asymptomatic HIV-positive adults in a placebo-controlled trial for 12 months, with a 3-6 year follow-up, reduced the risk of developing TB by 83% in PPD-positive individuals and by 71 % in the group 0vera11.~'
Conclusion
HIV infection is a contributing factor to the deteriorating TB situation in the developing world and amongst at-risk groups in some European and American cities, creating a new challenge to those charged with TB control. In the developing world, the control, treatment and prophylaxis of TB may offer the greatest chance of prolonging the lives of those with AIDS, in the same way that treatment and chemoprophylaxis of Pneumocystis carinii, toxoplasmosis and other opportunist infections have prolonged the lifespan of those with AIDS in the developed world. Thus a recent computer modelg9 predicted that in communities where 20% of the population was infected with HIV and 25% of those with TB were receiving treatment, TB-related deaths would be 100 YO higher than in communities where noone was infected with HIV. In a country with a population the size of Uganda's, this would lead to an extra 530000 deaths over a decade. If 50 YO of patients with active TB received treatment, one death would be averted for every 2.5 people receiving treatment. 99 The transmission cycle would also be interrupted.
A hgh index of suspicion of TB in all patients, combined with accurate and early diagnosis by conventional and molecular techniques, and prompt and aggressive chemotherapy with multiple agents will help to avert or ameliorate an impending international disaster. 
